No Data
WUXI BIO: Annual Report 2024
Guotou Securities: The investment and financing environment for Innovative Drugs is rebounding, CXO Orders and performance improvements are expected.
Global investment and financing in Innovative Drugs continues to improve, and a recovery in R&D demand is anticipated; new Orders are recovering in a timely manner, and there is optimism for improved CXO performance in 2025.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
Wuxi Biologics' Growth Trajectory Stable But Tariff Risks Linger -- Market Talk
WUXI BIO (02269) issued 4.1654 million shares due to the exercise of Options.
WUXI BIO (02269) announced that from April 14 to April 23, 2025, due to the exercise of Options...
